X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare, Analyse Fulford India with TEVA PHARMACEUTICAL INDUSTRIES LTD. - Israel - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

FULFORD INDIA vs TEVA PHARMA (Israel) - Comparison Results

FULFORD INDIA    Change

Fulford (India) Limited is an Indian affiliate of Schering-Plough Corporation, USA. The company has presence in oncology, virology and cardiovascular segments. In FY06 the topline of the company grew by 15.5% to Rs. 1519 m from Rs. 1279 m in FY05. PA... More

TEVA PHARMA (Israel)
   Change

Teva Pharmaceuticals, established in 1901, is a global pharmaceutical company. The company is into development, production and marketing of a wide range of specialty medicines, generic and OTC products, active pharmaceutical ingredients (API) and nov... More

DO YOU LIKE THESE REPORTS? TELL US!

Financials

 FULFORD INDIA   TEVA PHARMA
EQUITY SHARE DATA
    FULFORD INDIA
Mar-14
TEVA PHARMA
Dec-13
FULFORD INDIA/
TEVA PHARMA
5-Yr Chart
Click to enlarge
High Rs9422,704-   
Low Rs4502,349-   
Sales per share (Unadj.) Rs691.41,551.8-  
Earnings per share (Unadj.) Rs11.596.9-  
Cash flow per share (Unadj.) Rs15.4222.4-  
Dividends per share (Unadj.) Rs2.0084.86-  
Dividend yield (eoy) %0.33.4 8.6%  
Book value per share (Unadj.) Rs380.01,723.8-  
Shares outstanding (eoy) m3.90848.00-   
Bonus/Rights/Conversions ---  
Price / Sales ratio x1.01.6 61.8%   
Avg P/E ratio x60.726.1 233.0%  
P/CF ratio (eoy) x45.311.4 398.9%  
Price / Book Value ratio x1.81.5 125.0%  
Dividend payout %17.487.5 19.9%   
Avg Mkt Cap Rs m2,7142,142,404 0.1%   
No. of employees `0000.444.9 1.0%   
Total wages/salary Rs m5050-   
Avg. sales/employee Rs Th6,073.029,278.9 20.7%   
Avg. wages/employee Rs Th1,137.40-   
Avg. net profit/employee Rs Th100.71,829.0 5.5%   
INCOME DATA
Net Sales Rs m2,6961,315,941 0.2%  
Other income Rs m1250-   
Total revenues Rs m2,8221,315,941 0.2%   
Gross profit Rs m-46360,371 -0.0%  
Depreciation Rs m15106,369 0.0%   
Interest Rs m1025,847 0.0%   
Profit before tax Rs m54228,155 0.0%   
Minority Interest Rs m01,036 0.0%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m0-149,771 0.0%   
Tax Rs m10-2,786 -0.3%   
Profit after tax Rs m4582,206 0.1%  
Gross profit margin %-1.727.4 -6.3%  
Effective tax rate %17.7-1.2 -1,448.1%   
Net profit margin %1.76.2 26.5%  
BALANCE SHEET DATA
Current assets Rs m1,738888,782 0.2%   
Current liabilities Rs m545775,093 0.1%   
Net working cap to sales %44.38.6 512.4%  
Current ratio x3.21.1 278.3%  
Inventory Days Days4891 53.4%  
Debtors Days Days496 4.5%  
Net fixed assets Rs m12429,815 0.0%   
Share capital Rs m393,239 1.2%   
"Free" reserves Rs m1,4430-   
Net worth Rs m1,4821,461,761 0.1%   
Long term debt Rs m0672,870 0.0%   
Total assets Rs m2,0773,007,347 0.1%  
Interest coverage x6.79.8 68.3%   
Debt to equity ratio x00.5 0.0%  
Sales to assets ratio x1.30.4 296.7%   
Return on assets %2.63.6 72.6%  
Return on equity %3.05.6 53.6%  
Return on capital %4.34.9 87.3%  
Exports to sales %00-   
Imports to sales %24.50-   
Net fx Rs m-6560-   
CASH FLOW
From Operations Rs m90209,693 0.0%  
From Investments Rs m105-74,303 -0.1%  
From Financial Activity Rs m-14-251,541 0.0%  
Net Cashflow Rs m181-116,151 -0.2%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster
The reporting currency for TEVA PHARMA (Israel) is United States Dollars. All data has been converted at 64.78 Rs / USD

Compare FULFORD INDIA With: MYLAN (US)  ADCOCK INGRAM (S. Africa)  ACTAVIS (US)  

Compare FULFORD INDIA With: DIVIS LABORATORIES  ALEMBIC LTD  UNICHEM LAB  CADILA HEALTHCARE  SANOFI INDIA  



Today's Market

Sensex Finishes Firm; Software & FMCG Stocks Gain(Closing)

Indian share markets finished the trading session well above the dotted line, snapping a three-day falling streak amid firm Asian markets.

Related Views On News

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

Sun Pharma: Tough US Scenario Continues to Hit Business (Quarterly Results Update - Detailed)

Nov 20, 2017

The company's India business recovers but the pricing pressure and USFDA issues continue to mar the US revenues.

Dr Reddy's: No Respite from Pricing Pressure in the US (Quarterly Results Update - Detailed)

Nov 13, 2017

Pricing pressure continued to haunt Dr Reddy's although there was a significant improvement in its businesses sequentially.

More Views on News

Most Popular

Follow India's Super Investors to Make Big Money in the Market Crash(The 5 Minute Wrapup)

Feb 8, 2018

Has the sell-off in the markets left India's super investors unduly worried?

The Era of Easy Money is Coming to an End. What Happens Now?(Vivek Kaul's Diary)

Feb 9, 2018

The easy money policy of the Federal Reserve of the United States, which drove up stock markets all over the world, is ending, with the Federal Reserve looking to shrink its balance sheet.

The Markets Want Your Money. Don't Give It to Them.(Smart Contrarian)

Feb 9, 2018

MFs are having a gala time taking money from over-eager investors and funneling it into equities. Smart investors, though, know better than to do that.

The Big Gamble(The Honest Truth)

Feb 15, 2018

Once you accept the fact that elections are round the corner and that this budget is geared to reach a 40% target, everything makes sense.

Rising Dominance of Mutual Funds(Chart Of The Day)

Feb 8, 2018

Domestic money flow into Indian equities surpassed foreign fund flows in the recent years. But will it continue in volatile market?

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

FULFORD INDIA SHARE PRICE


Jul 30, 2015 (Close)

TRACK FULFORD INDIA

  • Track your investment in FULFORD INDIA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

FULFORD INDIA - PIRAMAL ENTERPRISES COMPARISON

COMPARE FULFORD INDIA WITH

MARKET STATS